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Abstract
Introduction: Sarcoidosis is a multisystem disease characterized by noncaseating granulomas in
the lungs, skin, lymph nodes, and, rarely, the nervous system. Granuloma formation in sarcoidosis
is mediated by increased secretion of interferon-gamma, interleukin-2, and tumor necrosis factor-
alpha. 25% of patients with neurosarcoidosis are steroid resistant and another 20–40% are resistant
to any conventional immunosuppression, but the typical agents suppress the immune system in a
non-specific fashion. Thalidomide has been shown to have activity specific to the inflammatory
mediators of sarcoidosis, has been shown to be beneficial in cutaneous sarcoidosis, and provides
an interesting observation in our patient with refractory neurosarcoidosis.
Case presentation: A 40 year old African-american female presented with refractory
neurosarcoidosis. Over the course of several years, the patient was treated with high dose
steroids, imuran, cytoxan, and cyclosporine without benefit. Then, the patient received
thalidomide, slowly escalating to 650 mg. After 2 months radiologic improvement was noted and
after 6 months clinical stabilization and improvement became apparent.
Conclusion:  Our case report presents a difficult, refractory case of neurosarcoidosis that
demonstrates an altered prognosis based on the addition of thalidomide.
Introduction
Sarcoidosis is a granulomatous, inflammatory disease that
most commonly involves the lungs, skin, and eyes, but
can also affect the nervous system in about 5% of cases
[1]. Though it is common for the disease to spontaneously
remit, nervous system involvement is a marker for a more
resistant course [2]. Because of this, nervous system
involvement is a definite indication for corticosteroid
treatment. Unfortunately, 25% will still have a refractory
course with steroid treatment and, even more concerning,
20–40% of those refractory patients will not respond to
any level of current conventional immunosuppression
[1,3].
Despite the identification of several possible candidates,
the exact inciting antigen responsible for the formation of
sarcoid granulomas remains uncertain. However, the
resultant inflammatory cascade involved in mediating
granuloma formation has been mapped out more accu-
rately. It involves macrophages or dendritic cells ingesting
the antigen with resultant peptide fragments bound to
MHC-II complexes that ignite a polarized TH-1 inflamma-
tory cascade. This involves Interleukin-2, Interleukin-12,
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interferon-gamma (IFN-γ), and tumor necrosis factor-
alpha (TNF-α). Specifically, TNF-α has gained clinical
attention with the availability of TNF-α blocking agents
[4]. The prognostic outcomes have been based on conven-
tional immunosuppression that attacks this process in a
non-specific fashion, but we present a case that contra-
dicted a refractory outcome after the patient received tha-
lidomide, which targets the immune cascade in a specific
fashion.
Case Presentation
A 40 year-old african-american female presented with a 3-
year history of headaches, episodes of altered awareness,
fatigue, back and neck pain, and progressive visual loss.
The headaches were the initial complaint and were con-
sidered migrainous in origin, but medications failed to
alter their building intensity. The progressive visual loss
then became more prominent and instigated a thorough
work-up.
The vision of the right eye was affected first (20/300 OD,
20/25 OS). A magnetic resonance imaging (MRI) scan of
the brain demonstrated bilateral optic nerve involvement,
so sarcoidosis was suspected, but a biopsy that included
tissue from the sclera, optic nerve sheath, and lacrimal
gland unfortunately was non-diagnostic. A chest CT and
serum ACE levels were initially normal, and a lumbar
puncture (wbc 9, protein 86, glucose 37, positive oligo-
clonal bands, negative cytology) had a normal ACE level,
as well. Though the above testing did not exclude the pos-
sibility of sarcoidosis, the lack of definitive findings
brought other possibilities into the differential diagnosis.
So, in addition to daily prednisone at 60 mg QD initiated
at the onset of visual deficits, the patient was also empiri-
cally given a one year trial of avonex for the potential diag-
nosis of "atypical MS." At that time her symptoms
consisted of right arm paresthesias and numbness, as well
as the aforementioned visual symptoms.
Notwithstanding these efforts, the patients' neurologic
status continued to decline, especially the vision in her left
eye, which was now becoming more clinically affected
(i.e., 20/200). The avonex was discontinued, and the
patient was started on imuran (50–100 mg/day), while
continuing prednisone (60–80 mg po QOD) over the
next 6 months. A repeat chest CT was performed, which
now showed grade I hilar adenopathy, so gallium scintig-
raphy was undertaken, which revealed bilateral increased
activity within the hilum, orbits, and mediastinum. Con-
sequently, a lung biopsy was performed, and this con-
firmed non-caseating granulomatous tissue, and a
diagnosis of neurosarcoidosis.
The patient's clinical decline continued, so more aggres-
sive immunosuppression was pursued. The patient
received four intravenous steroid pulses and two treat-
ment cycles of intravenous cyclophosphamide. Leukope-
nia prevented further treatment with cyclophosphamide.
However, oral cyclosporine was started at 25 mg po BID
to accompany oral prednisone at 60 mg po QOD.
Throughout the next seven months, while on this more
aggressive immunosuppressive regimen, the patient had
further deterioration. She lost all functional vision,
including light perception. The headaches persisted and
the back and neck pain became more severe, with a more
prominent radicular component. The patient required a
cane for ambulation, and often required the use of a
wheelchair, due to the extremity pain and visual loss. In
addition, migratory paresthesias became more promi-
nent. The patient's spells of altered awareness were found
to be complex partial seizures, and the patient required
management with levetiracetam (titrated to 1000 mg tid).
Repeat MRI of the brain (see figure 1) had also progressed,
now showing more prominent enhancement and thicken-
ing of the optic nerves, bilaterally (up to 6 mm in greatest
thickness). The thickness of the infundibulum had also
increased, up to 6 mm. Overall, meningeal enhancement
was more diffuse throughout the brain.
Due to the refractory nature of the neurosarcoidosis, the
patient investigated multiple opinions and was referred
for a trial of thalidomide. The patient was started on 50
MRI findings one month before initiation of thalidomide,  showing marked enhancement of infundibulum (6 mm) and  bilateral optic nerves (6 mm) Figure 1
MRI findings one month before initiation of thalidomide, 
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mg po BID of thalidomide with the goal of slowly titrating
up to a maximum dose of 800 mg per day. The patient was
titrated up to 650 mg per day over a 6 month time period,
but due to excessive fatigue and sedation, could not toler-
ate a higher dose.
After two months of treatment, the patient had radio-
graphic improvement on follow-up MRI scan (see figure
2). Following another 4 to 10 months of thalidomide,
there was complete resolution of all abnormal enhance-
ment on MRI, which has been maintained over the past
several years (see figure 3).
Following six months of therapy, her symptoms began to
stabilize and then slowly resolve. The radicular neck and
back pain markedly improved, with resultant facilitation
of her ambulation. Migratory paresthesias lessened and
headaches became much less severe. In addition, the com-
plex partial seizures were stabilized. The only poor out-
come was a lack of significant improvement in the vision.
Over the next year, cyclosporine was discontinued and
prednisone was slowly weaned to 5 mg per day. Through-
out this wean, the previously noted clinical improvements
remained stable.
The only significant side effect attributed to the thalido-
mide was sedation, which did limit the peak dose to 650
mg per day, even with a slow titration schedule. Due to
the favorable clinical response, following several years of
therapy, the dose has slowly been weaned down to 300
mg per day. The patient is stable on this dose, and plans
are for further weaning, as tolerated. The patient did have
some transient numbness and paresthesias in her feet, but
this resolved on the lower dose of thalidomide. She has
had no definite evidence of thalidomide neuropathy.
Discussion
Thalidomide, an immunomodulatory agent has the abil-
ity to inhibit all of the inflammatory mediators specific to
sarcoidosis, and, particularly, has very potent activity
against TNF-α [5]. With its known success in cutaneous
sarcoidosis, thalidomide might offer a better outcome for
patients with refractory neurosarcoidosis [5]. In this
report, we have described a patient that might further cor-
roborate this hypothesis.
Thalidomide was introduced as a hypnotic in the 1940's
and was well tolerated until its teratogenic effects were dis-
covered (i.e., phycomelia). It was pulled from the market
but gained a resurgence for the treatment of leprosy and
other conditions needing significant anti-inflammatory
effects [6]. Most importantly, it has shown efficacy against
cutaneous sarcoidosis, making it a potential candidate for
neurosarcoidosis, as well. Dosages from 100–800 mg per
day are used, with a slow titration towards 800 mg, if tol-
erated [5]. The main side effect that may potentially limit
treatment is sedation. Other side effects to be aware of
include rash, thromboembolism, dizziness, constipation,
MRI brain with contrast showing near resolution of enhance- ment, stable on serial MRIs for 2 years Figure 3
MRI brain with contrast showing near resolution of enhance-
ment, stable on serial MRIs for 2 years.
MRI Brain with contrast demonstrating improvement 2  months after initiation of thalidomide Figure 2
MRI Brain with contrast demonstrating improvement 2 
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and a painless, axonal sensory neuropathy that develops
in about 20% of patients. Because of the significant tera-
togenic concern, thalidomide can only be prescribed if the
physician is a member of the STEPS (System for Thalido-
mide Education and Prescribing Safety) program [7].
Interestingly, there is not an increased risk of infection in
patients on thalidomide, which is in contrast to other
immunosuppressive therapies used for sarcoidosis [6].
The patient in our case report appeared to respond well to
thalidomide without significant side effects, except dose-
limiting fatigue and somnolence. This is encouraging and
could further bolster experimental use of this medication
in refractory neurosarcoidosis, with the eventual possibil-
ity of clinical trials.
The patient had progressive clinical symptoms and wors-
ening of MRI findings (see figure 1), with increased
enhancement, despite high dose steroids and other
aggressive immunosuppressive medications. It is interest-
ing to note that the radiographic progression of enhanc-
ing brain lesions despite treatment correlates with a 75%
chance of a refractory course, further strengthening the
argument that this patient's prognosis was poor [8]. After
the initiation of thalidomide, the patient noted a plateau
of clinical symptoms within 6 months, and then demon-
strated steady continual improvement thereafter, except
for the visual loss. The lack of improvement of vision sug-
gested that the optic apparatus (i.e., optic nerves, chiasm,
optic tracts) was too severely damaged from sarcoidosis-
mediated inflammation (i.e., axonal loss) to allow recov-
ery. The 2 month follow-up scan (see figure 2) after tha-
lidomide was started, as well as subsequent scans (see
figures 3) after that, convincingly showed improvement
until resolution of the enhancement 6–12 months later.
Arguments against thalidomide providing this benefit
include that the disease naturally burned itself out or that
the conventional immunosuppressive agents did not have
enough time or high enough dosages to provide benefit.
Though it is possible that the disease process burned itself
out, it seems unlikely in a patient who had been refractory
for years with actively increasing inflammation on serial
MRIs immediately prior to the initiation of thalidomide.
Also, the patient had complex partial seizures, and sei-
zures are another known association with a typically
refractory course [9]. Initiation of more aggressive immu-
nosuppressive agents than steroids was attempted for 6
months with imuran, two courses of intravenous cyclo-
phosphamide, and for 7 months with cyclosporine prior
to initiation of thalidomide. Even though these medica-
tions can take months to show clinical benefit, it is
unlikely that the patient would have eventually
responded, since she was still progressing after 6 months
of therapy. Nevertheless, it is true that the patient only
received two full courses of intravenous cyclophospha-
mide, and the dose of cyclosporine was lower than target
doses for treatment in sarcoidosis. At a total dose of 50 mg
per day for the cyclosporine (25 mg po BID), this is lower
than the initial dose range of up to 4–6 mg/kg/day divided
up BID quoted in the literature for use in neurosarcoidosis
[4]. So, even though it seems likely that the patient had a
true failure of conventional immunosuppressive treat-
ment, due to the above extenuating circumstances, we are
only be able to firmly conclude that the patient had neu-
rosarcoidosis refractory to high dose corticosteroids.
Nevertheless, thalidomide yielded a dramatic response in
the current patient. We recommend further clinical evalu-
ation of this medication for treatment of patients with
neurosarcoidosis that are refractory to corticosteroids and
other conventional immunosuppressive therapy.
Conclusion
Our case report presents a difficult, refractory case of neu-
rosarcoidosis that demonstrates an altered prognosis
based on the addition of thalidomide.
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